ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer

您当前的位置：

首页 >

文章列表页 >

Short communication | 更新时间：2023-08-29

- ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
- Genes & Diseases Vol. 10, Issue 5, (2023)
- 作者机构：
  
  1. The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences,TX,Houston,USA,77030
  2. Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center,TX,Houston,USA,77030
  3. Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center,TX,Houston,USA,77030
  4. Hubei Hongshan Laboratory, College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University,Hubei,Wuhan,China,430070
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.09.013
  CLC：
- Published：2023，
  
  Published Online：1 September 2023，
扫描看全文
Ying Mei, Qinglei Hang, Hongqi Teng, et al. ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer. [J]. Genes & Diseases 10(5).(2023)
DOI：

Ying Mei, Qinglei Hang, Hongqi Teng, et al. ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer. [J]. Genes & Diseases 10(5).(2023) DOI： 10.1016/j.gendis.2022.09.013.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰